栄研化学(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4549/E00961 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2022/03/11 | 日証協 | 347,625株 | +12.31% | 234,852株 | +0.76% | 528,331株 | +6.11% | 90,585株 | +73.59% |
2022/03/04 | 日証協 | 309,525株 | -13.88% | 233,083株 | +61.07% | 497,929株 | -10.3% | 52,182株 | -57.72% |
2022/02/25 | 日証協 | 359,425株 | -10.35% | 144,711株 | -70.96% | 555,128株 | -30.05% | 123,426株 | -50.15% |
2022/02/18 | 日証協 | 400,925株 | -14.52% | 498,349株 | +109.81% | 793,613株 | +9.65% | 247,616株 | +276.75% |
2022/02/10 | 日証協 | 469,014株 | +6.6% | 237,524株 | -30.84% | 723,745株 | +1.68% | 65,724株 | -34.62% |
2022/02/04 | 日証協 | 439,958株 | -9.86% | 343,422株 | +48.6% | 711,760株 | -9.9% | 100,525株 | +58.59% |
2022/01/28 | 日証協 | 488,073株 | +1.39% | 231,106株 | -28.61% | 789,959株 | +2.61% | 63,385株 | -56.78% |
2022/01/21 | 日証協 | 481,373株 | +22.6% | 323,734株 | +30.22% | 769,830株 | +12.42% | 146,671株 | +38.63% |
2022/01/14 | 日証協 | 392,623株 | +9.97% | 248,600株 | +13.9% | 684,759株 | +15.35% | 105,800株 | +35.25% |
2022/01/07 | 日証協 | 357,023株 | +4.25% | 218,260株 | -2.44% | 593,659株 | +1.51% | 78,226株 | +7.3% |
2021/12/30 | 日証協 | 342,475株 | 0% | 223,728株 | 0% | 584,821株 | 0% | 72,901株 | 0% |
2021/12/24 | 日証協 | 342,475株 | +0.53% | 223,728株 | +0.03% | 584,821株 | +1.56% | 72,901株 | -21.02% |
2021/12/17 | 日証協 | 340,684株 | +0.31% | 223,654株 | -33.79% | 575,853株 | +4.37% | 92,300株 | -33.12% |
2021/12/10 | 日証協 | 339,633株 | +7.12% | 337,778株 | -12.27% | 551,767株 | +17.82% | 138,014株 | -52.97% |
2021/12/03 | 日証協 | 317,064株 | +148.47% | 385,023株 | +309.86% | 468,313株 | +89.57% | 293,485株 | +1503.57% |
2021/11/26 | 日証協 | 127,604株 | -12.21% | 93,940株 | -36.46% | 247,042株 | -1.87% | 18,302株 | -67.43% |
2021/11/19 | 日証協 | 145,345株 | +23.04% | 147,837株 | -4.26% | 251,760株 | +3.37% | 56,189株 | -59.34% |
2021/11/05 | 日証協 | 101,831株 | +13.77% | 86,845株 | -9.19% | 294,373株 | +23.67% | 77,857株 | -55% |
2021/10/29 | 日証協 | 89,506株 | +22.86% | 95,635株 | +99.22% | 238,038株 | +22.23% | 173,023株 | +55.49% |
※株式分割は考慮していませんのでご注意ください。
Page Top